Biotech · Private company
Oncopeptides AB
Track this companyFree. Adds Oncopeptides AB to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- DexamethasonePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- MelflufenPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- BortezomibPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Relapsed and/or Relapsed-refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · RRMMClinicalTrials.gov · fetched Nov 12, 2026
- MelflufenPhase 2 · Relapsed and/or Relapsed-refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- MelphalanPhase 2 · RRMMClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan flufenamide (Melflufen)Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 1 · AL AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan-Flufenamide (Melflufen)Phase 1 · AL AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasoneRelapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan FlufenamideRelapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) AmyloidosisPHASE1 · TERMINATED · started Aug 6, 2020ClinicalTrials.gov NCT04115956 · fetched Nov 12, 2026
- A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM PatientsPHASE2 · TERMINATED · started Aug 4, 2020ClinicalTrials.gov NCT04412707 · fetched Nov 12, 2026
- Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMPHASE1_PHASE2 · TERMINATED · started Apr 12, 2018ClinicalTrials.gov NCT03481556 · fetched Nov 12, 2026
- A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomidePHASE3 · TERMINATED · started Jun 12, 2017ClinicalTrials.gov NCT03151811 · fetched Nov 12, 2026
- A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPHASE2 · COMPLETED · started Dec 28, 2016ClinicalTrials.gov NCT02963493 · fetched Nov 12, 2026
- Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsPHASE1_PHASE2 · TERMINATED · started Jul 1, 2013ClinicalTrials.gov NCT01897714 · fetched Nov 12, 2026
- Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple MyelomaAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT04534322 · fetched Nov 12, 2026